CN Mobile Logo

Search form


Oncology and Hematology News and Journal Articles

New Treatment Options and Management Considerations in Borderline Resectable Pancreatic Cancer

In this article we will discuss the definitions of resectability, describe the current diagnostic tests for pancreatic cancer, and review strategies for maximizing treatment outcomes in patients with resectable pancreatic cancer.

Recent Content

In this interview we discuss some of the novel therapeutics in development for HER2-amplified breast cancer.

Limiting Medicaid enrollment has the potential for negative health impacts, in particular among low-income women with a diagnosis of breast cancer, according to a new study.

A 57-year-old man presents with hematuria, and a bladder biopsy is obtained. What is your diagnosis?

A biosimilar to trastuzumab known as CT-P6 showed equivalent efficacy and similar toxicity to the original agent in patients with HER2-positive breast cancer.

The addition of two cycles of neoadjuvant chemotherapy to concurrent chemoradiotherapy improved tumor control in patients with nasopharyngeal carcinoma.

Treatment with single-agent bevacizumab resulted in an improved disease-free interval in patients with resected melanoma, but no increase in overall survival compared with observation.

The primary tumor location was an independent prognostic marker in patients with RAS wild-type metastatic colorectal cancer after multivariable adjustment.

By clicking Accept, you agree to become a member of the UBM Medica Community.